Lecanemab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 691 publications

Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges.

Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges.

Journal: The Senior care pharmacist

Published: April 12, 2026

Correction to "Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: A multicenter real-world study".

Correction to "Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: A multicenter real-world study".

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 08, 2026

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.

Journal: Journal of Alzheimer's disease : JAD

Published: April 03, 2026

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.

Journal: Journal of managed care & specialty pharmacy

Published: March 26, 2026

Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.

Comparison table: Amyloid beta-directed antibodies for Alzheimer's disease.

Journal: The Medical letter on drugs and therapeutics

Published: March 24, 2026

Drugs for dementia.

Drugs for dementia.

Journal: The Medical letter on drugs and therapeutics

Published: March 24, 2026

Comparison table: Drugs for Alzheimer's disease dementia.

Comparison table: Drugs for Alzheimer's disease dementia.

Journal: The Medical letter on drugs and therapeutics

Published: March 24, 2026

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy.

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy.

Journal: Journal of Alzheimer's disease : JAD

Published: March 20, 2026

Lecanemab alters basement membrane collagen IV in viable microvessels isolated from brains with high Alzheimer's disease neuropathology.

Lecanemab alters basement membrane collagen IV in viable microvessels isolated from brains with high Alzheimer's disease neuropathology.

Journal: Journal of Alzheimer's disease : JAD

Published: March 20, 2026

Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal.

Alzheimer's drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal.

Journal: BMJ (Clinical research ed.)

Published: March 20, 2026

Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review.

Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review.

Journal: Journal of Alzheimer's disease : JAD

Published: March 16, 2026

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507].

Journal: The journal of prevention of Alzheimer's disease

Published: March 14, 2026

Showing 1-12 of 691

Last Updated: 04/28/2026